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Abstract Rho proteins and phosphatidylinositide 3-kinases (PI
3-kinases) have been widely implicated in regulating cell motility
both in cultured cells and in animal models. Monocytes are
recruited from the bloodstream in response to inflammatory
signals, and migrate across the endothelial barrier into the
tissues, where they differentiate into macrophages and phagocy-
tose bacteria and cells. Studies of monocytes and macrophages
have revealed that different Rho family members and PI 3-
kinases are not functionally redundant but play unique and
distinct roles in motile responses. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Neutrophils and macrophages are the body’s ¢rst line of
defence against invading micro-organisms. Macrophages not
only phagocytose micro-organisms, infected cells and dying
cells, but release a battery of cytokines that are key to initiat-
ing and maintaining in£ammatory and immune responses.
However, macrophages can also play a negative role in
chronic in£ammatory diseases such as rheumatoid arthritis,
multiple sclerosis and atherosclerosis. Macrophages are there-
fore a prime target for therapies aimed at treating chronic
in£ammatory diseases. In order to understand how macro-
phage-mediated tissue damage can be e¡ectively inhibited, it
is essential to elucidate the mechanisms whereby they are re-
cruited to and activated in tissues. This review addresses the
roles of speci¢c signalling proteins in the motile responses of
monocytes and macrophages, in their recruitment both out of
blood vessels and into tissues, and in their subsequent activity
as phagocytes (Fig. 1).
2. Rho proteins
The Rho protein family is part of the Ras superfamily of
small GTPases. There are at least 20 genes encoding Rho
family members in mammals, including Rho (A, B, C), Rac
(1, 2, 3), Cdc42, TC10, TCL, RhoD, RhoG, RhoE/Rnd3,
Rnd1, Rnd2, Chp (1, 2), RhoBTB (1, 2), Rif and TTF. In
addition, splice variants of Rac1 and Cdc42 have been de-
scribed. Many of these proteins have been studied for their
e¡ects on the actin cytoskeleton, and in some cases on cell^
cell adhesion, vesicle tra⁄cking, cell cycle progression and
transcriptional activation [1]. However, nearly all studies on
cell migration have concentrated on the roles of Rho, Rac and
Cdc42, and very little is known about how other Rho family
members in£uence cell migration. Rho, Rac and Cdc42 were
the ¢rst members of the family to be characterised for their
roles in regulating the actin cytoskeleton: Rho stimulates ac-
tomyosin-based contractility and induces actin organisation
into stress ¢bres in many but not all cell types; Rac induces
the extension of lamellipodia, involving actin polymerisation
at the plasma membrane; while Cdc42 induces the extension
of ¢nger-like plasma membrane protrusions known as ¢lopo-
dia, which again are driven outward through actin polymeri-
sation.
Most Rho proteins bind and hydrolyse GTP, and change
conformation depending on whether they are bound to GTP
or GDP (Fig. 2). When bound to GTP, they are ‘active’, in
that they can then interact with and activate their downstream
signalling partners. Hydrolysis of GTP to leave them bound
to GDP releases them from their signalling partners, thereby
terminating the response. They can be reactivated by guanine
nucleotide exchange factors (GEFs), which induce release of
bound nucleotide (generally GDP) and thereby allow GTP to
bind. GTP hydrolysis is catalysed by GTPase activating pro-
teins (GAPs), which thereby act to downregulate the response
to Rho proteins. Rho proteins are normally post-translation-
ally modi¢ed by prenylation at the carboxy-terminus, and this
is important for their association with membranes. A further
level of regulation is provided for some Rho proteins by gua-
nine nucleotide dissociation inhibitors, which form an inactive
complex with the Rho protein in the cytoplasm, masking the
prenyl group and preventing it from interacting with the plas-
ma membrane.
A number of point mutants have been useful in de¢ning the
functions of Rho family proteins (Fig. 1). First, constitutively
active versions of the proteins can be generated by mutating
residues that play essential roles in the catalysis of GTP hy-
drolysis. These mutations lock the proteins in their GTP-
bound conformation, as they are unable to hydrolyse GTP
to GDP. By introducing these into cells, it is possible to
¢nd out the consequences of not being able to turn the pro-
teins o¡. Second, dominant negative mutations act to prevent
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the activation of their endogenous counterparts, and thus tell
us what the consequence of not being able to turn the proteins
on is. How these dominant negative proteins act is not known
in most cases, although at least with Rac and Cdc42 they have
been shown to have very low a⁄nity for nucleotide, especially
GTP, and thus may act primarily by binding to exchange
factors and preventing them acting on endogenous Rac or
Cdc42 respectively. Third, a battery of other point mutations
have been useful in dissecting out the roles of di¡erent do-
mains of each protein in mediating distinct downstream re-
sponses in cells. For example, mutation of amino acid 40 in
Rac prevents binding in vitro to one of its downstream signal-
ling partners, PAK [2,3]. In cells, this mutant can still induce
lamellipodium extension [3].
3. PI 3-kinases
Phosphatidylinositide 3-kinases (PI 3-kinases) are involved
in regulating a number of cellular responses, including cell
growth, survival and migration [4]. PI 3-kinases are a family
of enzymes that add a phosphate to the 3P position of the
inositide ring of phosphatidylinositides (for review see [4]).
They are divided into three classes, based on sequence simi-
larity and biochemical properties. Class I PI 3-kinases are best
established for their roles in signal transduction, and act to
generate phosphatidylinositol 3,4,5-triphosphate at the plasma
membrane in response to extracellular stimuli. Class Ia PI 3-
kinases consist of a catalytic subunit, p110 (K, L or N), and an
adapter subunit, generally p85 (K or L). The p85 subunit binds
to phosphorylated tyrosines on signalling proteins and trans-
membrane receptors, leading to the recruitment and activation
of the p110 subunits at the plasma membrane. There is only
one class Ib PI 3-kinase, which consists of a catalytic subunit,
p110Q, and probably an associated p101 subunit [5]. PI 3-ki-
nase Q is recruited and activated by G protein-coupled recep-
tors.
A number of reagents have been used to study the function
of PI 3-kinases. First, LY294002 and wortmannin are two
small molecule inhibitors of PI 3-kinases and act relatively
speci¢cally to inhibit nearly all PI 3-kinase isoforms [5]. In
addition, introduction of mutated tyrosine kinase receptors
that no longer bind the p85 adapters have been used to im-
plicate class 1a PI 3-kinases in speci¢c responses induced by
growth factor receptors. An alternative approach is to express
a dominant negative form of p85.
Class I PI 3-kinases can act upstream of Rac but so far
there is no good evidence that they act upstream of any other
Rho family members. One mechanism whereby they could
activate Rac is through phosphatidylinositol trisphosphate-in-
duced activation of Rac GEFs such as Vav, Sos and Tiam1
[6,7]. However, it is also possible for Rac to be activated
independently of PI 3-kinase activity [8].
4. Monocyte endothelial adhesion and diapedesis
Monocyte transmigration across endothelial cells is the ¢rst
step required for the recruitment of monocytes into tissues.
Monocytes transmigrate across quiescent endothelial cells at
very low rates, but the rate of transmigration is massively
increased following endothelial cell activation. A variety of
factors stimulate endothelial cells and enhance transmigration,
including the pro-in£ammatory cytokines tumour necrosis
factor-K and interleukin-1, which stimulate leukocyte trans-
migration primarily by inducing the expression of adhesion
receptors (including E-selectin, ICAM-1 and VCAM-1) and
chemokines on the apical surface of endothelial cells [9].
Monocyte adhesion and transmigration involves a two-way
signalling process between monocytes and endothelial cells. E-
selectin can mediate weak adhesion of leukocytes to endothe-
lial cells, allowing leukocytes to slow down and ‘roll’ on the
endothelial surface. Chemokines can then activate leukocyte
integrins, which in turn adhere to ICAM-1 and VCAM-1,
leading to ¢rm adhesion of leukocytes to the endothelial sur-
face. Recent data indicate that endothelial cells are themselves
activated through engagement of monocyte binding receptors,
including E-selectin, ICAM-1 and VCAM-1. Antibody-in-
duced clustering of any of these receptors can induce Rho-
mediated stress ¢bre formation in endothelial cells, as well as
tyrosine phosphorylation of a number of proteins [10^12].
Fig. 1. Motile responses of monocytes/macrophages. Monocytes in
the bloodstream adhere to activated endothelial cells, and then
transmigrate across junctions between endothelial cells. Once outside
blood vessels, they di¡erentiate into macrophages and migrate to-
wards a site of infection or in£ammation, and then extend their
plasma membrane to engulf the particle by phagocytosis.
Fig. 2. Regulation of Rho proteins. Rho cycles between an active
GTP-bound conformation and an inactive GDP-bound conforma-
tion. In resting cells, most Rho is bound in an inactive complex in
the cytoplasm with GDIs (guanine nucleotide dissociation inhibi-
tors). Incoming signals from extracellular factors such as lysophos-
phatidic acid (LPA) release Rho from GDIs and activate guanine
nucleotide exchange factors (GEFs) to stimulate exchange of GDP
for GTP on Rho. Rho-GTP can then interact with downstream tar-
gets, such as the serine/threonine kinases ROK and PRK, and the
adapter protein Dia. Rho is inactivated by GTP hydrolysis, cata-
lysed by GTPase activating proteins (GAPs). Mutants of Rho pro-
teins that are used to analyse protein function include constitutively
active mutants that are impaired in GTP hydrolysis (mutation of
amino acids 14 in Rho from Gly to Val, and 63 from Glu to Leu),
and dominant negative mutants (mutation of amino acid 19 in Rho
from Thr to Asn). A number of bacterial toxins, such as the Clostri-
dium botulinum exoenzyme C3 transferase, are also used to inhibit
or activate Rho proteins.
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Rho activation in turn is important for stabilising the inter-
action between monocytes and endothelial cells [10]. In con-
trast, inhibition of Rac or Cdc42 has no discernible e¡ect on
monocyte adhesion.
5. Macrophage chemotaxis
Following tissue damage or invasion of micro-organisms,
tissue macrophages are rapidly recruited to the site of damage.
In addition, once monocytes have crossed the endothelial bar-
rier, they di¡erentiate into macrophages and migrate from the
blood vessels to sites of in£ammation. Macrophage chemotax-
is can be induced by small peptides known as chemokines
produced during in£ammation, as well as by the cytokine
colony-stimulating factor-1 (CSF-1), which is both a survival
factor and a chemoattractant for macrophages.
CSF-1 stimulates the tyrosine kinase receptor c-fms to acti-
vate a variety of signalling pathways [13,14]. Like other tyro-
sine kinase receptors, c-fms can recruit class 1a PI 3-kinases
through their p85 adapter proteins [13]. Studies on a mouse
macrophage cell line, Bac1.2F5, have shown that both PI 3-
kinases and Rho GTPases are required for CSF-1-induced
migration [15,16]. Inhibition of the p110L and p110N isoforms
of PI 3-kinase by injecting isoform-speci¢c antibodies impairs
lamellipodium extension and macrophage migration (Fig. 2),
whereas antibodies to the p110K isoform inhibit cell prolifer-
ation but not migration [16]. The relative involvement of dif-
ferent p110 isoforms in migration appears to be cell type-de-
pendent. For example, in porcine aortic endothelial cells,
which express p110K and L but not p110N, p110K is required
for plasmid-derived growth factor-induced migration whereas
p110L is required for insulin-induced migration [17].
In CSF-1-induced migration, both Rho and Rac are re-
quired for migration, but play distinct roles (Fig. 3A)
[15,18]. Rac is required for lamellipodium extension and for-
mation of new adhesions to the extracellular matrix. Rho
stimulates actomyosin-mediated contractility [19], and inacti-
vation of Rho reduces intracellular tension so that macro-
phages extend very long processes with lamellipodia at their
tips. The cell body remains stationary and is unable to follow
the leading lamella, hence cell migration is prevented. In con-
trast to Rac and Rho, Cdc42 is not required for cell migration
but is required for sensing the chemotactic gradient of CSF-1.
When Cdc42 is inhibited cells migrate randomly despite the
presence of a chemotactic gradient [15]. Cdc42 is also required
for polarity generation in other systems. For example, in Cae-
norhabditis elegans it is involved in generating cell polarity in
early embryos [20,21]. In addition, Cdc42 is required for T
cells to polarise towards antigen-presenting cells [22].
Little is known about the roles of Rho GTPases in chemo-
kine-induced macrophage chemotaxis, although studies in T
cells have shown that Rho, Rac, Cdc42 and and the Cdc42
target WASp are required for chemotaxis of T cells towards
the chemokine SDF-1 [23,24]. Chemokines act through G
protein-coupled receptors, and in mice lacking the class 1b
p110Q PI 3-kinase macrophage migration towards a variety
of chemokines is impaired [25^28].
6. Phagocytosis
The ¢nal goal of macrophages is to phagocytose invading
micro-organisms, virally infected cells, dying (apoptotic) cells
and other debris at sites of infection and in£ammation. At the
same time, macrophages produce a range of cytokines and
chemokines that modulate the recruitment and activation of
further macrophages and other leukocytes and lymphocytes.
Macrophages generally phagocytose through the recognition
of molecules on the surface of objects, including immunoglob-
ulins, the complement component C3b, and phosphatidylser-
ine on apoptotic cells. Phagocytosis is dependent on actin
polymerisation, but di¡erent Rho proteins are implicated in
the uptake of di¡erent types of particles. Phagocytosis of im-
munoglobulin-coated particles and apoptotic cells requires
Rac and Cdc42 but not Rho (Fig. 3B) [29^31], whereas uptake
of C3b-coated particles requires Rho but not Rac or Cdc42
[31]. PI 3-kinases have been implicated in the phagocytic up-
take of immunoglobulin-coated particles, C3b-coated par-
ticles, and apoptotic cells [29,32,33]. Which isoforms of PI
3-kinase mediate these responses is not known, although it
appears that p110Q is unlikely to be involved from studies
on p110Q-null mice [25,26]. Interestingly, however, in contrast
to chemotaxis, where PI 3-kinases appear to act upstream of
Rac, PI 3-kinases act at a later stage to Rac during phagocy-
tosis of immunoglobulin-coated particles and apoptotic cells.
PI 3-kinases are not required for actin-driven membrane pro-
trusion around particles, but appear to act at a later stage to
inhibit membrane fusion [29,33].
Fig. 3. Model for the regulation of macrophage functions by PI 3-
kinases and Rho proteins. (A) Migrating cells extend lamellipodia at
their leading edge, and this is dependent on PI 3-kinases and Rac-
driven actin polymerisation. They also form new adhesions to the
extracellular matrix in lamellipodia, and this requires Rac activity.
The cell body follows the front of the cell through Rho-induced ac-
tomyosin contraction. Detachment of the tail is probably also de-
pendent on this Rho-driven contraction. Directional sensing (chemo-
taxis) requires Cdc42, which induces the extension of ¢lopodia. (B)
Macrophages phagocytose apoptotic cells and antibody-coated par-
ticles by extending their plasma membrane around the particle. This
is dependent on Rac and Cdc42, and requires actin polymerization.
PI 3-kinases act at a later stage and may promote membrane fusion
and ¢nal engulfment of the particle.
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7. Conclusions
Both PI 3-kinases and Rho proteins play important roles at
multiple steps in the recruitment and activation of macro-
phages, and these proteins are therefore potentially good can-
didates for therapies aimed at treating chronic in£ammatory
diseases. Of the isoforms studied, each makes a di¡erent con-
tribution to motile responses. Inhibiting Rho, for example,
reduces both monocyte transmigration and macrophage che-
motaxis, although it does not reduce phagocytosis of immu-
noglobulin-coated particles or apoptotic cells. In the future, it
will be interesting to ¢nd out how other members of the Rho
family a¡ect cell migration, as well as to determine how iso-
form-speci¢c functions of PI 3-kinases are mediated.
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